Multidisciplinary team (MDT) for skin cancer

A team of health professionals will work with you to plan the treatment that is best for your situation.

What is a MDT?

In most hospitals, a team of specialists will talk to you about the treatment they feel is best for your situation. This multidisciplinary team (MDT) will include:

  • a dermatologist (skin disease specialist)
  • a general surgeon
  • a plastic surgeon
  • a medical oncologist (chemotherapy specialist)
  • a clinical oncologist (radiotherapy and chemotherapy specialist)
  • a skin cancer nurse specialist
  • radiologists, who analyse x-rays and scans
  • pathologists, who advise on the type and extent of the cancer.

The specialists will talk to you about your treatment options, and about what to expect. They will answer any questions you have. You may be asked if you would like to take part in a clinical trial.

Discussing your treatment

If you have any questions about your treatment, ask your doctor or nurse to explain things to you. It often helps to make a list of questions and to take a relative or close friend with you. They can remind you of questions you want to ask and help you remember what was said.

Your MDT will plan the most suitable treatment for you. Many people are happy with the treatment plan, but some people want a second opinion.

You will need to give permission (consent) before any treatment starts.

About our information

  • References

    Below is a sample of the sources used in our skin cancer information. If you would like more information about the sources we use, please contact us at

    Motley et al. British Association of Dermatologists. Management of the patient with primary cutaneous squamous cell carcinoma. 2009.

    National Institute for Health and Care Excellence (NICE). NG12: Suspected cancer: recognition and referral. 2015 (updated 2017).

    National Institute for Health and Care Excellence (NICE). NG134: Sunlight Exposure: Benefits and Risks. 2016.

    National Institute for Health and Care Excellence (NICE). PH32: Skin Cancer Prevention. 2011 (updated 2016).

    Scottish Intercollegiate Guidelines Network (SIGN) 140. Management of primary cutaneous squamous cell carcinoma. 2014.

    Telfar N et al. Guidelines for the management of basal cell carcinoma. British Journal of Haematology. 2008.

  • Reviewers

    This information has been written, revised and edited by Macmillan Cancer Support’s Cancer Information Development team. It has been reviewed by expert medical and health professionals and people living with cancer. It has been approved by Senior Medical Editor, Professor James Larkin, Consultant Medical Oncologist.

    Our cancer information has been awarded the PIF TICK. Created by the Patient Information Forum, this quality mark shows we meet PIF’s 10 criteria for trustworthy health information.